Radiomics-Based Imaging Tool May Predict Response to... : Oncology Times

"Immunotherapy has profoundly changed the management of multiple cancers," said Roger Sun, MD, PhD candidate under Eric Deutsch, MD, PhD, and Charles Ferté, MD, PhD, at the laboratory INSERM U1030 at Gustave Roussy in Villejuif, France. "However, most patients do not respond to this type of treatment. That is why we need to identify biomarkers that allow identification of patients who are most likely to respond to immunotherapy." Studies utilizing biopsy samples of tumor tissues have confirmed the link between immune-cell infiltration into tumors and patients' treatment responses; however, Sun noted, because cancers are heterogeneous, biopsies only reflect the local aspect of the tumor. "Medical computational imaging, also known as radiomics, is a new field of research that aims to translate standard imaging like CT, MRI, or PET into objective data and use them as biomarkers," he explained.